Granted Patent
B2
US 12,247,059 · App. 17/373,665 · Granted Mar 11, 2025
Conjugates of an IL-2 moiety and a polymer
Inventors:
Mary J. Bossard (Madison, AL); Cherie F. Ali (Burlingame, CA); Xiaofeng Liu (Belmont, CA); Deborah H. Charych (Albany, CA); Yujun Wang (Fremont, CA)
Assignee:
Nektar Therapeutics
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Conjugates of an interleukin-2 (“IL-2”) moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the non-peptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, methods of administering compositions to an individual, nucleic acid sequences, expression systems, host cells, and methods for preparing IL-moieties.
Claims (15)
1. A composition comprising a conjugate of an interleukin-2 (IL-2) moiety, the conjugate comprising from three to seven branched poly(ethylene glycol) polymers, each covalently attached via a releasable linkage to an amino group of the IL-2 moiety, wherein the IL-2 moiety is aldesleukin, each branched poly(ethylene glycol) has a weight average molecular weight from about 20,000 daltons to about 85,000 daltons, and the composition possesses no IL-2 activity prior to in vivo release of the branched poly(ethylene glycol) polymer(s) from the conjugate.
2. The composition of claim 1 , wherein each branched poly(ethylene glycol) polymer is terminally capped with an alkoxy end-capping moiety.
3. The composition of claim 1 , wherein each branched poly(ethylene glycol) polymer is covalently attached at an amino group of a lysine of the IL-2 moiety.
4. The composition of claim 1 , wherein three or four branched poly(ethylene glycol) polymers are attached to the IL-2 moiety.
5. The composition of claim 1 , wherein each branched poly(ethylene glycol) polymer has a weight average molecular weight of about 20,000 daltons.
6. The composition of claim 5 , wherein each branched poly(ethylene glycol) polymer comprises two poly(ethylene glycol) chains.
7. The composition of claim 1 , wherein the composition comprises a plurality of the conjugates comprising from three to seven branched poly(ethylene glycol) polymers covalently attached to the IL-2 moiety, and the composition possesses no IL-2 activity prior to in vivo release of the branched poly(ethylene glycol) polymer(s) from the conjugates comprised in the composition.
8. The composition of claim 6 , wherein the composition comprises a plurality of the conjugates comprising from three to seven branched poly(ethylene glycol) polymers covalently attached to the IL-2 moiety, and the composition possesses no IL-2 activity prior to in vivo release of the branched poly(ethylene glycol) polymer(s) from the conjugates comprised in the composition.
9. The composition of claim 8 , wherein the plurality of conjugates is a mixture of conjugates selected from the group of conjugates having four, five, six and seven branched poly(ethylene glycol) polymers covalently attached to the IL-2 moiety.
10. The composition of claim 9 , wherein the plurality of conjugates is a mixture of conjugates having an average of six branched poly(ethylene glycol) polymers per interleukin-2 moiety.
11. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable excipient.
12. The composition of claim 11 , in a form suitable for injection.
13. The composition of claim 11 , in the form of a lyophilate for reconstitution with a pharmaceutically acceptable diluent.
14. The composition of claim 11 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of carbohydrates, inorganic salts, buffers, acids, bases, and combinations thereof.
15. A method of treating a patient with cancer, the method comprising administering to the patient a pharmaceutical composition of claim 11 .
Continuity (5)
Division
13884901
Provisional Application
61413236
· Nov 12, 2010
References Cited (134)
US 4401756A
· Gillis
· 1983
[cited by applicant]
US 4705848A
· Yang et al.
· 1987
[cited by applicant]
US 4766106A
· Katre et al.
· 1988
[cited by applicant]
US 4902502A
· Nitecki et al.
· 1990
[cited by applicant]
US 5078997A
· Hora et al.
· 1992
[cited by applicant]
US 5089261A
· Niteck et al.
· 1992
[cited by applicant]
US 5116943A
· Koth et al.
· 1992
[cited by applicant]
US 5153310A
· Mitchell et al.
· 1992
[cited by applicant]
US 5206344A
· Katre et al.
· 1993
[cited by applicant]
US 5419899A
· Koths et al.
· 1995
[cited by applicant]
US 5614185A
· Koths et al.
· 1997
[cited by applicant]
US 5635597A
· Barrett et al.
· 1997
[cited by applicant]
US 5739208A
· Harris
· 1998
[cited by applicant]
US 5932462A
· Harris et al.
· 1999
[cited by applicant]
US 6034072A
· Ralston et al.
· 2000
[cited by applicant]
US 6180095B1
· Greenwald et al.
· 2001
[cited by applicant]
US 6706289B2
· Lewis et al.
· 2004
[cited by applicant]
US 7101965B2
· Theze et al.
· 2006
[cited by applicant]
US 7511094B2
· Kozlowski
· 2009
[cited by examiner]
US 7585837B2
· Shechter et al.
· 2009
[cited by applicant]
US 9861705B2
· Bossard
· 2018
[cited by examiner]
US 20040136952A1
· Bhaskaran et al.
· 2004
[cited by applicant]
CN 101104077A
· 2008
[cited by applicant]
EP 0473268
· 1992
[cited by applicant]
EP 0510356A1
· 1992
[cited by applicant]
EP 1688146
· 2006
[cited by applicant]
KR 1020090103209
· 2009
[cited by applicant]
WO WO8700056A1
· 1987
[cited by applicant]
WO WO9012874
· 1990
[cited by applicant]
WO WO9945964
· 1999
[cited by applicant]
WO WO9960128
· 1999
[cited by applicant]
WO WO0162827
· 2001
[cited by applicant]
WO WO0200243
· 2002
[cited by applicant]
WO WO2004060300
· 2004
[cited by applicant]
WO WO2004089280
· 2004
[cited by applicant]
WO WO2005000360A2
· 2005
[cited by applicant]
WO WO2006138572A2
· 2006
[cited by applicant]
WO WO2007075534A2
· 2007
[cited by applicant]
WO WO2007117685A2
· 2007
[cited by applicant]
WO WO2008082669A2
· 2008
[cited by applicant]
WO WO2008106186A2
· 2008
[cited by applicant]
WO WO2009139905A2
· 2009
[cited by applicant]
WO WO2010033207A1
· 2010
[cited by applicant]
Greenwald et al (Bioconjugate Chem. 2003, 14, 395-403) (Year: 2003).
[cited by examiner]
Katre et al (Proc Natl Acad Sci U S A. Mar. 1987;84(6):1487-91) (Year: 1987).
[cited by examiner]
Kegg data sheet for Aldesleukin (downloaded Jan. 13, 2024 from https://www.genome.jp/dbget-bin/www_bget?dr:D00748) (Year: 2024).
[cited by examiner]
Knauf et al (J Biol Chem. Oct. 15, 1988;263(29):15064-70) (Year: 1988).
[cited by examiner]
Abuchowski, et al., “Cancer Therapy with Chemically Modified Enzymes. I. Antitumor Properties of Polyethylene Glycol-Asparaginase Conjugates”, Cancer Biochem. Biophys., vol. 7, pp. 175-186, (1984).
[cited by applicant]
Arakawa, et al., “Structure and solubility of interleukin-2 in sodium dodecyl sulfate,” International Journal of Peptide & Protein Research, vol. 43, pp. 583-587, (1994).
[cited by applicant]
Bork, “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle”, Genome Res., vol. 10, pp. 398-400, (2000).
[cited by applicant]
Bowie, et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”, Science, vol. 247, No. 4948, pp. 1306-1310, (1990).
[cited by applicant]
Burgess, et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Singl…
[cited by applicant]
Chen, et al., “Plasma and Lymph Pharmacokinetics of Recombinant Human Interleukin-2 and Polyethylene Glycol-Modified Interleukin-2 in Pigs,” The Journal of Pharmacology and Experimental Therapeutics, vol. 293, No. 1, pp…
[cited by applicant]
Devlin, et al., “Alteration of amino-terminal codons of human granulocyte-colony-stimulating factor increases expression levels and allows efficient processing by methionine aminopeptidase in
[cited by applicant]
Goodson, et al., “Site-Directed Pegylation of Recombinant Interleukin-2 at its Glycosylation Site,” Bio/Technology, vol. 8, pp. 343-346, (1990).
[cited by applicant]
Greenwald, et al., “Controlled Release of Proteins from Their Poly(Ethylene Glycol) Conjugates: Drug Delivery Systems Employing 1,6-Elimination,” Bioconjugate Chem., vol. 14, pp. 395-403, (2003).
[cited by applicant]
Harris, et al., “Effect of Pegylation on Pharmaceuticals”, Nat. Rev. Drug Discov., vol. 2, No. 3, pp. 214-221, (2003).
[cited by applicant]
Heldt, et al., “The Use of Glycidol to Introduce Aldehyde Functions Into Proteins—Application to the Fluorescent Labelling of Bovine Serum Albumin and Avidin,” Eur. J. Org. Chem., vol. 32, pp. 5429-5433, (2007).
[cited by applicant]
Hora, et al., “Controlled Release of Interleukin-2 From Biodegradable Microspheres,” Bio/Technology, vol. 8, pp. 755-758, (1990).
[cited by applicant]
Katre, et al., “Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model,” Proc. Natl. Acad. Sci. USA, vol. 84, pp. 1487-1491, (1987).
[cited by applicant]
Knauf, et al., “Relationship of Effective Molecular Size to Systemic Clearance in Rats of Recombinant Interleukin-2 Chemically Modified with Water-soluble Polymers,” The Journal of Biological Chemistry, vol. 263, No. 29…
[cited by applicant]
Lazar, et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities”, Mol. Cell Biol., vol. 8, No. 3, pp. 1247-1252, (1988).
[cited by applicant]
Luchansky, et al., “Metabolic Functionalization of Recombinant Glycoproteins,” vol. 43, No. 38, pp. 12358-12366, (2004).
[cited by applicant]
Moreau, et al., Characterization of a Monoclonal Antibody Directed Against the NH2 Terminal Area of Interleukin-2 (IL-2) and Inhibiting Specifically the Binding of IL-2 to IL-2 Receptor β Chain (IL-2Rβ), Molecular Immun…
[cited by applicant]
Ouchi, et al., “Design of Antitumor Agent-Terminated Poly(Ethylene Glycol) Conjugate as Macromolecular Prodrug,” Polymer Preprints, vol. 38, No. 1, pp. 582-583, (1997).
[cited by applicant]
Pauly, et al., “Isolation of Interleukin 2 (IL-2) from Human and Mouse Lymphocyte Culture Supernatants by Batch Adsorption onto Silicic Acid,” Journal of Immunological Methods, vol. 75, pp. 73-84, (1984).
[cited by applicant]
Samlowski, et al., “ReGel® Polymer-based Delivery of Interleukin-2 as a Cancer Treatment,” J. Immunother., vol. 29, No. 5, pp. 524-535, (2006).
[cited by applicant]
Shechter, et al., “Prolonging the half-life of human interferon-α2 in circulation: Design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)
[cited by applicant]
Shechter, et al., “Suspensions of pro-drug insulin greatly prolong normoglycemic patterns in diabetic rats,” Biochemical and Biophysical Research Communications, vol. 307, pp. 315-321, (2003).
[cited by applicant]
Shechter, et al., “Reversible PEGylation of peptide YY
[cited by applicant]
Shechter, et al., “Reversible pegylation of insulin facilitates its prolonged action in vivo,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 70, pp. 19-28, (2008).
[cited by applicant]
Sims, et al., “A Method for the Estimation of Polyethylene Glycol in Plasma Protein Fractions,” Analytical Biochemistry, vol. 107, pp. 60-63, (1980).
[cited by applicant]
Teppler, et al., “Prolonged Immunostimulatory Effect of Low-Dose Polyethylene Glycol Interleukin 2 in Patients with Human Immunodeficiency Virus Type 1 Infection,” J. Exp. Med., vol. 177, pp. 483-492, (1993).
[cited by applicant]
Tsubery, et al., “Prolonging the Action of Protein and Peptide Drugs by a Novel Approach of Reversible Polyethylene Glycol Modification,” The Journal of Biological Chemistry, vol. 279, No. 37, pp. 38118-38124, (2004).
[cited by applicant]
Yang, et al., “Murine Studies Using Polyethylene Glycol-Modified Recombinant Human Interleukin 2 (PEG-IL-2): Antitumor Effects of PEG-IL2 Alone and in Combination with Adoptive Cellular Transfer,” Lymphokine and Cytokin…
[cited by applicant]
Yang, et al., “The Use of Polyethylene Glycol-Modified Interleukin-2 (PEG-IL-2) in the Treatment of Patients with Metastatic Renal Cell Carcinoma and Melanoma,” Cancer, vol. 76, No. 4, pp. 687-694, (1995).
[cited by applicant]
Young, et al., “Two-step total gene synthesis method,” Nucleic Acids Research, vol. 32, No. 7, e59, pp. 1-6, (2004).
[cited by applicant]
Zalipsky, et al., “Attachment of Drugs to Polyethylene Glycols”, Eur. Polym. J., vol. 19, No. 12, pp. 1177-1183, (1983).
[cited by applicant]
Zalipsky, et al., “Chemistry of polyethylene glycol conjugates with biologically active molecules”, Advanced Drug Delivery Reviews, vol. 16, pp. 157-182, (1995).
[cited by applicant]
Zalipsky, et al., “Use of Functionalized Poly(Ethylene Glycol)s for Modification of Polypeptides”, in Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications, edited by J. Milton Harris, Plenum Press, …
[cited by applicant]
Zimmerman, et al., “Schedule Dependency of the Antitumor Activity and Toxicity of Polyethylene Glycol-modified Interleukin 2 in Murine Tumor Models,” Cancer Research, vol. 49, pp. 6521-6528, (1989).
[cited by applicant]
PCT International Search Report and Written Opinion corresponding to PCT International Application No. PCT/US2011/060408 date of mailing Mar. 26, 2012.
[cited by applicant]
PCT International Preliminary Report on Patentability corresponding to PCT International Application No. PCT/US2011/060408 date of mailing May 23, 2013.
[cited by applicant]
Enzon Pharmaceuticals, Macromolecular Engineering Technologies, 16 pages, (2004).
[cited by applicant]
Nektar™—Transforming Therapeutics, Nektar Molecule Engineering: Polyethylene Glycol and Derivatives for Advanced PEGylation, 24 pages, Catalog—2003, (Jul. 2003).
[cited by applicant]
Nektar™—Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, 27 pages, Catalog—2004, (Jul. 2004).
[cited by applicant]
Nektar™—Transforming Therapeutics, Nektar Advanced PEGylation: Polyethylene Glycol and Derivatives for Advanced PEGylation, 33 pages, (Catalog 2005-2006).
[cited by applicant]
NOF Corporation, PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals, 46 pages, Catalogue 2003—1
[cited by applicant]
NOF Corporation, PEG Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals, 27 pages, Catalogue 2003—2
[cited by applicant]
NOF Corporation, PEG Derivatives, Phospholipids and Drug Delivery Materials for Pharmaceutical Products and Formulations, 60 pages, Catalogue Ver. 8, (Apr. 2006).
[cited by applicant]
Polypure Products, PEG amines; PEG acids and amino acids; PEG thiols and disulfides; Biotins, 5 pages, (Apr. 2004).
[cited by applicant]
Polypure Products, PEG amines; PEG acids and amino acids; PEG thiols and disulfides; Biotins, 5 pages, (Apr. 2005).
[cited by applicant]
Quanta Biodesign, Labeling, Derivatization and Crosslinking Reagents for Biological and Related Materials with dPEG™, 38 pages, (Mar. 12, 2004).
[cited by applicant]
Quanta Biodesign, Labeling, Modification and Crosslinking Reagents incorporating our unique monodispersed dPEG™ Technology, 31 pages, (Nov. 5, 2004).
[cited by applicant]
Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG™ (dPEG™) derivatives, (Product Catalog), 26 pages, (Updated: Jul. 18, 2005).
[cited by applicant]
Quanta Biodesign, Ltd., Leading innovator, producer and provider of monodisperse discrete PEG™ (dPEG™) derivatives, (Product Catalog), 26 pages, (Updated: Nov. 17, 2005).
[cited by applicant]
Shearwater Polymers, Inc., Polyethylene Glycol Derivatives, 50 pages, Catalog—(Mar. 1995).
[cited by applicant]
Shearwater Polymers, Inc., Polyethylene Glycol Derivatives, 55 pages, Catalog 1997-1998, (Jul. 1997).
[cited by applicant]
Shearwater Polymers, Inc., Polyethylene Glycol and Derivatives: Functionalized Biocompatible Polymers for Research and Pharmaceuticals, 50 pages, Catalog—(Jan. 2000).
[cited by applicant]
Shearwater Corporation, Polyethylene Glycol and Derivatives for Biomedical Applications, 20 pages, Catalog—(Jul. 2001).
[cited by applicant]
Australian Patent Examination Report No. 1 corresponding to Australian Patent No. 2011325990 date of issue Feb. 15, 2016.
[cited by applicant]
Canadian Office Communication corresponding to Canadian Patent Application No. 2,816,722 dated Sep. 8, 2017.
[cited by applicant]
First Office Action corresponding to Chinese Patent Application No. 201180064511.4, date of notification Sep. 10, 2014.
[cited by applicant]
Chinese Notification of the Second Office Action corresponding to Chinese Patent Application No. 201180064511.4 dated Jul. 15, 2015.
[cited by applicant]
English Translation of Notification of the Third Office Action corresponding to Chinese Patent Application No. 201180064511.4 date of notification Mar. 22, 2016.
[cited by applicant]
English Translation of Notification of the Fourth Office Action corresponding to Chinese Patent Application No. 201180064511.4 date of notification Dec. 12, 2016.
[cited by applicant]
Official Action in Eurasian Patent Application No. 201390697, 3 pages, (Jan. 2015).
[cited by applicant]
Eurasian Official Action corresponding to Eurasian Patent Application No. 201390697 dated Aug. 15, 2015.
[cited by applicant]
English Translation of Official Action corresponding to Eurasian Patent Application No. 201390697 dated Apr. 18, 2016.
[cited by applicant]
European Communication corresponding to European Patent Application No. 11840401.1 dated May 25, 2016.
[cited by applicant]
European Communication corresponding to European Patent Application No. 11840401.1 dated Nov. 7, 2017.
[cited by applicant]
English Translation of an Office Communication corresponding to Israeli Patent Application No. 226267 dated Jul. 3, 2016.
[cited by applicant]
English Translation of an Office Communication corresponding to Israeli Patent Application No. 226267 dated Oct. 31, 2017.
[cited by applicant]
Japanese Notice of Reasons for Rejection corresponding to Japanese Patent Application No. 2013-538940 mailing date Sep. 2, 2015.
[cited by applicant]
English Translation of Notice of Reasons for Rejection corresponding to Japanese Patent Application No. 2013-538940 mailing date May 18, 2017.
[cited by applicant]
English Translation of Examination Report corresponding to Mexican Patent Application No. MX/a/2013/005363 dated Oct. 13, 2017.
[cited by applicant]
Arakawa et al., “Structure of Unfolded and Refolded Recombinant Derived [Ala
[cited by applicant]
Pettit et al., “Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling”, The Journal of Biological Chemistry, vol. 272, No. 4, Issue of Jan. …
[cited by applicant]
English Translation of Official Action corresponding to Eurasian Patent Application No. 201390697 dated Apr. 28, 2017.
[cited by applicant]
English Translation of Notice of Final Rejection corresponding to Japanese Patent Application No. 2013-538940 mailing date May 2, 2016.
[cited by applicant]
English Translation of Pre-Approval Examination Report corresponding to Japanese Patent Application No. 2013-538940 mailing date Dec. 12, 2016.
[cited by applicant]
English Translation of Notice of Reasons for Rejection corresponding to Japanese Patent Application No. 2013-538940 mailing date Dec. 1, 2017.
[cited by applicant]
English Translation of Notice of Grounds for Rejection corresponding to Korean Patent Application No. 10-2013-7014802 issuance date Aug. 17, 2018.
[cited by applicant]